The Effects of Sarcopenia on Neuromuscular Block in Gastrointestinal Cancer Surgery

Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Observational
SUMMARY

This prospective observational study aims to evaluate the effects of sarcopenia on intraoperative neuromuscular block (NMB) in patients undergoing gastrointestinal cancer surgery. Adult patients scheduled for elective gastrointestinal cancer surgery will be grouped as sarcopenic or non-sarcopenic based on preoperative abdominal CT scans. Neuromuscular block parameters, including onset time, depth, duration, and recovery, will be objectively measured using TOF (Train-of-Four) monitoring. The study seeks to determine whether sarcopenia influences sensitivity to muscle relaxants and to contribute to individualized anesthesia management and patient safety.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: t
View:

• Patients aged between 18 and 75 years

• Patients diagnosed with gastrointestinal system (GIS) cancer and scheduled for elective surgery

• Patients who have undergone preoperative abdominal computed tomography (CT) imaging

• Patients classified as American Society of Anesthesiologists (ASA) physical status I-III

Locations
Other Locations
Turkey
Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital Clinic of Anesthesiology and Rea
RECRUITING
Ankara
Contact Information
Primary
Mustafa Kemal SAHIN
mksahin@msn.com
+905075800976
Time Frame
Start Date: 2025-06-01
Estimated Completion Date: 2025-09-20
Participants
Target number of participants: 100
Treatments
Sarcopenic
Patients with gastrointestinal cancer scheduled for elective surgery who are identified as sarcopenic based on preoperative abdominal CT scans at the L3 vertebral level, according to established cut-off values.
Non-Sarcopenic
Patients with gastrointestinal cancer scheduled for elective surgery who are identified as non-sarcopenic based on preoperative abdominal CT scans at the L3 vertebral level, according to established cut-off values.
Related Therapeutic Areas
Sponsors
Leads: Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital

This content was sourced from clinicaltrials.gov